When I opened ASCO url, saw banner ad for Roche metmab trial. Completion date Dec 2015 and only 450 participants globally (according to the clinical trials website, most sites not recruiting yet...but maybe that site is not up-to-date). Trying to crawl back to $6 here...who thought we'd be in this situation? Big picture, right now, no appetite globally for risk. German bonds now offer 0% with plenty of takers.
<Trying to crawl back to $6 here...who thought we'd be in this situation?> The secondary offering has done it. The ARQL management needed money and did not want to take any chances.
<Roche MetMab trial will have 450 participants globally> The ARQ197 will have 1,000* pts. If ARQ 197 is almost as good as MetMab, the 375-pts pick will be enough for the trial stoppage and to proceed with the ARQ 179 registration!